Nemaura Announces Positive Initial Data from H2H CGM Study; Mylan Q1 '20 Earnings Update
Here is a brief preview of this blast: Two diabetes-related news items have been observed: Nemaura Medical announced positive early data from a H2H trial of sugarBEAT vs. an undisclosed incumbent CGM device and Mylan hosted its Q1 '20 earnings call. Below, FENIX provides highlights of the news items as well as thoughts on where sugarBEAT may fit within the CGM market.